These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 20683405)

  • 21. Clinical significance of enlarged cardiophrenic lymph nodes in advanced ovarian cancer: Implications for survival.
    Mert I; Kumar A; Sheedy SP; Weaver AL; McGree ME; Kim B; Cliby WA
    Gynecol Oncol; 2018 Jan; 148(1):68-73. PubMed ID: 29129390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Follow-up study of the correlation between postoperative computed tomographic scan and primary surgeon assessment in patients with advanced ovarian, tubal, or peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease of 1 cm or smaller.
    Chi DS; Barlin JN; Ramirez PT; Levenback CF; Mironov S; Sarasohn DM; Iyer RB; Dao F; Hricak H; Barakat RR
    Int J Gynecol Cancer; 2010 Apr; 20(3):353-7. PubMed ID: 20375796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term survival in patients with para-aortic lymph node metastasis with systematic retroperitoneal lymphadenectomy followed by adjuvant chemotherapy in endometrial carcinoma.
    Hiura M; Nogawa T; Matsumoto T; Yokoyama T; Shiroyama Y; Wroblewski J
    Int J Gynecol Cancer; 2010 Aug; 20(6):1000-5. PubMed ID: 20683408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abdominopelvic cytoreduction rates and recurrence sites in stage IV ovarian cancer: is there a case for thoracic cytoreduction?
    Perri T; Ben-Baruch G; Kalfon S; Beiner ME; Helpman L; Hogen LB; Shapira-Frommer R; Korach J
    Gynecol Oncol; 2013 Oct; 131(1):27-31. PubMed ID: 23880152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pleural effusion detected at CT prior to primary cytoreduction for stage III or IV ovarian carcinoma: effect on survival.
    Mironov O; Ishill NM; Mironov S; Vargas HA; Zheng J; Moskowitz CS; Sonoda Y; Papas RS; Chi DS; Hricak H
    Radiology; 2011 Mar; 258(3):776-84. PubMed ID: 21193598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Robella M; Vaira M; Marsanic P; Mellano A; Borsano A; Cinquegrana A; Sottile A; De Simone M
    Minerva Chir; 2014 Feb; 69(1):27-35. PubMed ID: 24675244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prognostic relevance of node metastases in optimally cytoreduced advanced ovarian cancer.
    Bachmann C; Brucker SY; Kraemer B; Rothmund R; Staebler A; Fend F; Wallwiener D; Grischke EM
    J Cancer Res Clin Oncol; 2015 Aug; 141(8):1475-80. PubMed ID: 25739827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma.
    Nelson BE; Rosenfield AT; Schwartz PE
    J Clin Oncol; 1993 Jan; 11(1):166-72. PubMed ID: 8418230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The significance of paracardiac lymph-node enlargement in patients with newly diagnosed stage IIIC ovarian cancer.
    Raban O; Peled Y; Krissi H; Goldberg N; Aviram A; Sabah G; Levavi H; Eitan R
    Gynecol Oncol; 2015 Aug; 138(2):259-62. PubMed ID: 26001327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lymph node-positive stage IIIC ovarian cancer: a separate entity?
    Berek JS
    Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S18-20. PubMed ID: 19955908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stage III disease of ovarian, tubal and peritoneal cancers can be accurately diagnosed with pre-operative CT. Japan Clinical Oncology Group Study JCOG0602.
    Onda T; Tanaka YO; Kitai S; Manabe T; Ishikawa M; Hasumi Y; Miyamoto K; Ogawa G; Satoh T; Saito T; Kasamatsu T; Nakanishi T;
    Jpn J Clin Oncol; 2021 Feb; 51(2):205-212. PubMed ID: 33556170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcome of Iranian patients with advanced ovarian cancer with neoadjuvant chemotherapy versus primary debulking surgery.
    Ghaemmaghami F; Karimi-Zarchi M; Modares-Gilani M; Mousavi A; Behtash N
    Asian Pac J Cancer Prev; 2008; 9(4):719-24. PubMed ID: 19256766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study.
    Eisenkop SM; Friedman RL; Wang HJ
    Gynecol Oncol; 1998 May; 69(2):103-8. PubMed ID: 9600815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of centralization of primary surgery on survival in ovarian cancer patients.
    Tingulstad S; Skjeldestad FE; Hagen B
    Obstet Gynecol; 2003 Sep; 102(3):499-505. PubMed ID: 12962932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic factors and the role of primary debulking in operable stage IVB ovarian cancer with supraclavicular lymph node metastasis: a retrospective study in Chinese patients.
    Quan C; Chen X; Wen H; Wu X; Li J
    BMC Cancer; 2024 May; 24(1):565. PubMed ID: 38711015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recurrent ovarian carcinoma of low malignant potential: the role of secondary surgical cytoreduction and the prognosis in Chinese patients.
    Zang RY; Yang WT; Shi DR; Xing Y; Cai SM
    J Surg Oncol; 2005 Jul; 91(1):67-72. PubMed ID: 15999350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic role of mesenteric lymph nodes involvement in patients undergoing posterior pelvic exenteration during radical or supra-radical surgery for advanced ovarian cancer.
    Berretta R; Capozzi VA; Sozzi G; Volpi L; Ceni V; Melpignano M; Giordano G; Marchesi F; Monica M; Di Serio M; Riccò M; Ceccaroni M
    Arch Gynecol Obstet; 2018 Apr; 297(4):997-1004. PubMed ID: 29380107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes.
    Bristow RE; Giuntoli RL; Pannu HK; Schulick RD; Fishman EK; Wahl RL
    Gynecol Oncol; 2005 Nov; 99(2):294-300. PubMed ID: 16051330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD.
    Chekerov R; Braicu I; Castillo-Tong DC; Richter R; Cadron I; Mahner S; Woelber L; Marth C; Van Gorp T; Speiser P; Zeillinger R; Vergote I; Sehouli J
    Int J Gynecol Cancer; 2013 Feb; 23(2):268-75. PubMed ID: 23358178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.